Premium
An IgG3 switch variant of rituximab mediates enhanced complement‐dependent cytotoxicity against tumour cells with low CD 20 expression levels
Author(s) -
Rösner Thies,
Derer Stefanie,
Kellner Christian,
Dechant Michael,
Lohse Stefan,
Vidarsson Gestur,
Peipp Matthias,
Valerius Thomas
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12209
Subject(s) - ofatumumab , complement dependent cytotoxicity , cd20 , rituximab , antibody , antigen , antibody dependent cell mediated cytotoxicity , immunology , isotype , cancer research , effector , monoclonal antibody , medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom